Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial

References

• Pneumonia: the forgotten killer of children [Internet]. UNICEF/WHO; [ cited February 2017]. Available from: http://www.childinfo.org/files/Pneumonia_The_Forgotten_Killer_of_Children.pdf
   Google Scholar
• Despite steady progress, pneumonia remains one of the single largest killers of young children worldwide [Internet]. UNICEF; [ cited February 2017]. Available from: http://data.unicef.org/child-health/pneumonia.html
   Google Scholar
• O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902.
   PubMed Web of Science ®Google Scholar
• Summary of WHO Position Papers - Recommended Routine Immunizations for Children [Internet]. WHO; [ cited February 2017]. Available from: http://www.who.int/immunization/policy/Immunization_routine_table2.pdf
   Google Scholar
• WHO. Pneumococcal vaccines  WHO position paper – 2012. Weekly Epidemiol Rec. 2012;87(14):129–144. Available from: http://www.who.int/wer/2012/wer8714.pdf
   Google Scholar
• Madhi SA, Cohen C, von Gottberg A. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy. Vaccine. 2012;30(Suppl 3):C21–27.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Adegbola RA, et al. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. Vaccine. 2011;29(18):3372–3373.
   PubMed Web of Science ®Google Scholar
• Schoub BD, Ngcobo NJ, Madhi S. The National Advisory Group on Immunization (NAGI) of the Republic of South Africa. Vaccine. 2010;28(Suppl 1):A31–34.
   PubMedGoogle Scholar
• WHO vaccine-preventable diseases: monitoring system. 2016 Global summary. Coverage time series for South Africa (ZAF) [Internet]. WHO; [ cited February 2017]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/coverages?c=ZAF
   Google Scholar
• Summary of product characteristics [Internet]. EMA; [ cited February 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000973/WC500054346.pdf
   Google Scholar
• Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: synflorix. Expert Rev Vaccines. 2009;8(11):1479–1500.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381(9862):214–222.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Nieminen H, et al. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial. Lancet Respir Med. 2014;2(9):717–727.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Saez-Llorens X, Lopez P, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial. Plos Med. 2014;11(6):e1001657.
   PubMed Web of Science ®Google Scholar
• Kilpi T, Palmu A, Puumalainen T et al. Effectiveness of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against hospital-diagnosed pneumonia in infants - FinIP trial. Paper presented at the 31st Annual Meeting of the European Society for Paediatric Infectious Diseases. 2013 May 28-Jun 1; Milan, Italy.
   Google Scholar
• Palmu AA, Kilpi T, Rinta-Kokko H et al. Impact of 10-valent pneumococcal conjugate vaccine (PCV10) against hospital-diagnosed pneumonia among vaccine-eligible children in Finland. Paper presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014 Sep 5-9; Washington, DC, USA.
   Google Scholar
• Silfverdal SA, Hogh B, Bergsaker MR, et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J. 2009;28(10):e276–282.
   PubMedGoogle Scholar
• Hamaluba M, Kandasamy R, Upreti SR, et al. Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15(4):405–414.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Koen A, Jose L, et al. Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status. Medicine (Baltimore). 2017;96(2):e5881.
   PubMed Web of Science ®Google Scholar
• Poolman JT, Frasch CE, Kayhty H, et al. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol. 2010;17(1):134–142.
   PubMed Web of Science ®Google Scholar
• Henckaerts I, Durant N, De Grave D, et al. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine. 2007;25(13):2518–2527.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005;5(2):83–93.
   PubMed Web of Science ®Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. Plos Med. 2010;7(10):e1000348.
   PubMed Web of Science ®Google Scholar
• Sirima SB, Tiono A, Gansane Z, et al. Immunogenicity and safety of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered to children with sickle cell disease between 8 weeks and 2 years of age: a phase III, open, controlled study. Pediatr Infect Dis. 2016;36(5):e136–e150.
   Google Scholar
• Silfverdal SA, Skerlikova H, Zanova M, et al. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life. Pediatr Infect Dis J. 2011;30(9):e155–163.
   PubMed Web of Science ®Google Scholar
• Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial. JAMA. 2013;310(9):930–937.
   PubMed Web of Science ®Google Scholar
• Ruckinger S, Dagan R, Albers L, et al. Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: a systematic review and meta-analysis. Vaccine. 2011;29(52):9600–9606.
   PubMed Web of Science ®Google Scholar
• Deloria Knoll M, Park DE, Johnson TS, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J. 2014;33(Suppl 2):S119–129.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Nunes MC. The potential impact of pneumococcal conjugate vaccine in Africa: considerations and early lessons learned from the South African experience. Hum Vaccin Immunother. 2016;12(2):314–325.
   PubMed Web of Science ®Google Scholar
• Conklin L, Loo JD, Kirk J, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J. 2014;33(Suppl 2):S109–118.
   PubMed Web of Science ®Google Scholar
• Loo JD, Conklin L, Fleming-Dutra KE, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J. 2014;33(Suppl 2):S140–151.
   PubMed Web of Science ®Google Scholar
• Loo JD, Conklin L, Fleming-Dutra KE, et al. Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr Infect Dis J. 2014;33(Suppl 2):S161–171.
   PubMed Web of Science ®Google Scholar
• Dicko A, Odusanya OO, Diallo AI, et al. Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial. BMC Public Health. 2011;11:882.
   PubMed Web of Science ®Google Scholar
• Dicko A, Santara G, Mahamar A, et al. Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children. Hum Vaccin Immunother. 2013;9(2):382–388.
   PubMed Web of Science ®Google Scholar
• Health and Related Indicators [Internet]. South Africa: health systems trust; [ cited February 2017]. Available from: http://www.hst.org.za/uploads/files/chap16_08.pdf
   Google Scholar
• Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–846.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Nieminen H, et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. Lancet Infect Dis. 2014;14(3):205–212.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Nieminen H, et al. Effectiveness of the ten-valent pneumococcal conjugate vaccine against tympanostomy tube placements in a cluster-randomized trial. Pediatr Infect Dis J. 2015;34(11):1230–1235.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Seppa I, et al. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) against carriage and acute otitis media-a double-blind randomized clinical trial in Finland. J Pediatric Infect Dis Soc. 2016;5(3):237–248.
   PubMed Web of Science ®Google Scholar
• De Wals P, Lefebvre B, Markowski F, et al. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine. 2014;32(13):1501–1506.
   PubMed Web of Science ®Google Scholar
• Sigurdsson S, Kristinsson KG, Erlendsdottir H, et al. Decreased incidence of respiratory infections in children after vaccination with ten-valent pneumococcal vaccine. Pediatr Infect Dis J. 2015;34(12):1385–1390.
   PubMed Web of Science ®Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study. Plos One. 2015;10(3):e0120290.
   PubMed Web of Science ®Google Scholar